Abeona Therapeutics Inc. ABEO
We take great care to ensure that the data presented and summarized in this overview for ABEONA THERAPEUTICS INC. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding ABEO
View all-
Suvretta Capital Management, LLC New York, NY3.69MShares$21.5 Million0.77% of portfolio
-
Nantahala Capital Management, LLC New Canaan, CT3.51MShares$20.5 Million0.75% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA2.69MShares$15.7 Million0.02% of portfolio
-
Western Standard LLC Los Angeles, CA2.28MShares$13.3 Million6.48% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.02MShares$11.8 Million0.0% of portfolio
-
Vivo Capital, LLC Palo Alto, CA1.84MShares$10.8 Million2.38% of portfolio
-
Laurion Capital Management LP New York, NY1.31MShares$7.63 Million0.16% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny810KShares$4.73 Million0.0% of portfolio
-
Susquehanna International Group, LLP Bala Cynwyd, PA761KShares$4.44 Million0.0% of portfolio
-
683 Capital Management, LLC New York, NY675KShares$3.94 Million0.26% of portfolio
Latest Institutional Activity in ABEO
Top Purchases
Top Sells
About ABEO
Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening rare genetic diseases. Its lead program is EB-101, an autologous, gene-corrected cell therapy that is in Phase III clinical trial for recessive dystrophic epidermolysis bullosa. The company also develops ABO-102, an adeno-associated virus (AAV)-based gene therapy for Sanfilippo syndrome type A; ABO-201 to treat CLN3 disease; ABO-401 for the treatment of cystic fibrosis; and ABO-50X for the treatment of genetic eye disorders. In addition, it is developing AAV-based gene therapy through its AIM vector platform programs. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was incorporated in 1974 and is headquartered in New York, New York.
Insider Transactions at ABEO
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jul 09
2025
|
Mark Alvino Director |
SELL
Open market or private sale
|
Direct |
13,093
-14.49%
|
$65,465
$5.86 P/Share
|
|
Jul 09
2025
|
Brendan M. O'Malley SVP, Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
17,428
-4.61%
|
$87,140
$5.86 P/Share
|
|
Jul 09
2025
|
Faith L. Charles Director |
SELL
Open market or private sale
|
Direct |
10,738
-7.17%
|
$53,690
$5.86 P/Share
|
|
Jul 09
2025
|
Joseph Walter Vazzano Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
25,411
-5.04%
|
$127,055
$5.86 P/Share
|
|
Jul 09
2025
|
Vishwas Seshadri Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
69,420
-5.32%
|
$347,100
$5.86 P/Share
|
|
Jul 09
2025
|
Christine Berni Silverstein Director |
SELL
Open market or private sale
|
Direct |
13,093
-9.8%
|
$65,465
$5.86 P/Share
|
|
Jul 08
2025
|
Donald A. Wuchterl Director |
SELL
Open market or private sale
|
Direct |
5,176
-3.44%
|
$25,880
$5.82 P/Share
|
|
Jun 06
2025
|
Vishwas Seshadri Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
50,676
-3.74%
|
$304,056
$6.76 P/Share
|
|
Jun 06
2025
|
Joseph Walter Vazzano Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
17,795
-3.5%
|
$106,770
$6.76 P/Share
|
|
Jun 06
2025
|
Brendan M. O'Malley SVP, Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
10,470
-2.69%
|
$62,820
$6.76 P/Share
|
|
Jun 05
2025
|
Joseph Walter Vazzano Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
13,333
+2.57%
|
-
|
|
Jun 01
2025
|
Vishwas Seshadri Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
885
-0.07%
|
$5,310
$6.24 P/Share
|
|
May 27
2025
|
Mark Alvino Director |
SELL
Open market or private sale
|
Direct |
2,000
-2.16%
|
$12,000
$6.38 P/Share
|
|
May 16
2025
|
Mark Alvino Director |
SELL
Open market or private sale
|
Direct |
8,000
-7.97%
|
$40,000
$5.68 P/Share
|
|
Mar 31
2025
|
Vishwas Seshadri Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
25,000
-1.81%
|
$100,000
$4.78 P/Share
|
|
Mar 14
2025
|
Joseph Walter Vazzano Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
685
-0.13%
|
$3,425
$5.29 P/Share
|
|
Mar 03
2025
|
Brendan M. O'Malley SVP, Chief Legal Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
181
-0.05%
|
$905
$5.24 P/Share
|
|
Jan 31
2025
|
Mark Alvino Director |
BUY
Grant, award, or other acquisition
|
Direct |
36,101
+26.44%
|
-
|
|
Jan 31
2025
|
Leila Alland Director |
BUY
Grant, award, or other acquisition
|
Direct |
36,101
+18.95%
|
-
|
|
Jan 31
2025
|
Bernhardt G Zeiher Director |
BUY
Grant, award, or other acquisition
|
Direct |
36,101
+43.37%
|
-
|
Last 12 Months Summary
| Grant, award, or other acquisition | 1.13M shares |
|---|
| Payment of exercise price or tax liability | 35.3K shares |
|---|---|
| Open market or private sale | 276K shares |